Periostin Secreted by Carcinoma-Associated Fibroblasts Promotes Ovarian Cancer Cell Platinum Resistance Through the PI3K/Akt Signaling Pathway | Zendy

Lei Chu | Zendy; Fangce Wang | Zendy; Wenjun Zhang | Zendy; Huaifang Li | Zendy; Jun Xu | Zendy; Xiaowen Tong | Zendy

Open Access

Periostin Secreted by Carcinoma-Associated Fibroblasts Promotes Ovarian Cancer Cell Platinum Resistance Through the PI3K/Akt Signaling Pathway

Author(s) -

Lei Chu,

Fangce Wang,

Wenjun Zhang,

Huaifang Li,

Jun Xu,

Xiaowen Tong

Publication year - 2020

Publication title -

technology in cancer research and treatment

Language(s) - English

Resource type - Journals

eISSN - 1533-0346

pISSN - 1533-0338

DOI - 10.1177/1533033820977535

Subject(s) - periostin , cancer research , stromal cell , downregulation and upregulation , protein kinase b , pi3k/akt/mtor pathway , ovarian cancer , cancer cell , stroma , signal transduction , chemistry , cancer , medicine , biology , microbiology and biotechnology , pathology , extracellular matrix , immunohistochemistry , biochemistry , gene

Periostin (POSTN) is a protein secreted by mesenchymal cells. Periostin is upregulated in several cancer types and overexpression is associated with poor prognosis. However, the functional role and molecular underpinnings of periostin in epithelial ovarian cancer (EOC) is unknown. In the present study, periostin was found to be significantly upregulated in EOC stroma. Functional studies revealed that periostin could decrease cisplatin (DDP)-induced apoptosis in EOC. Periostin led to DDP resistance in EOC cells, potentially through the PI3K/Akt signaling pathway. We generated periostin-overexpressing fibroblasts and found that EOC cells were resistant to DDP when co-cultured with periostin-overexpressing fibroblasts. The findings of the present study indicated that periostin secreted by cancer-associated stromal cells may be a potential therapeutic target for EOC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research